Type 1 Diabetes Mouse Models
Test your novel investigational therapy’s effect on glycemic control and glucose tolerance thanks to InnoSer’s expertise in Type 1 diabetes mouse models
Type 1 Diabetes mouse models are established either via chemical induction (e.g., STZ or alloxan-induced diabetes) or via genetic modifications (e.g., NOD mouse model). STZ or alloxan chemically-induced models result in targeted beta cell destruction and are flexible for finetuning the level of beta cell ablation and the degree of hypoglycemia. The genetic NOD mouse model is prone to T1D development via autoimmune islet destruction, making them of particular interest to evaluate immune-modulatory drugs. Key readouts include glucose tolerance testing, evaluation of immune cell infiltration and islet destruction, beta cell and islet evaluation, blood biomarkers, hormone quantification, and histological and clinical endpoints.
InnoSer’s type 1 diabetes mouse models and readouts, therefore, arise as suitable efficacy models for therapies aimed to target auto-immunity, promote beta-cell regeneration, and facilitate research of novel approaches ranging from (stem) cell therapies, small molecules to hormone modulating approaches or gene therapies. Test your novel investigational therapy’s efficacy on glycemic control and glucose tolerance in a fast and golden standard experimental diabetes mouse model with full tailoring flexibility.
Developing new, safe and efficacious therapies is an extremely intricate process. As a preclinical immunology contract research organisation (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo immunology drug development portfolio.
Type 1 diabetes mouse models characteristics:
- Chemically induced (Alloxan, STZ) type 1 diabetes in mice.
- Study comorbidities such as diabetic kidney disease development.
- Suitable for assessment of novel ATMPs such as cell therapy or other regenerative strategies.
- Complementary in vitro immunoassays, histopathology analyses and PK/PD profiling services.
Key readouts in the type 1 diabetes mouse model:
Test the efficacy of your treatments in the IL-23 induced psoriasis mouse model with the following readouts:
- Glucose monitoring blood and urine
- Insulin secretion
- Blood biomarkers
- Glucose Tolerance Testing via IPGTT, OGTT
- Islet cell composition
- In vitro glucose-stimulated insulin secretion (GSIS)
- Diabetic kidney disease (glomerular atrophy) complications assessment
- Histopathology (islet atrophy, insulitis, inflammation; evaluation of beta cell regeneration)
- Inflammatory cytokines via MSD
- Immune cell profiling (spleen, lymph nodes, PBMCs) via flow cytometry
Example data featuring type 1 diabetes mouse model:
Early Signs of Diabetic Kidney Disease Following Alloxan-Induced T1D in Mice: Morphological and Biochemical Changes
Following chemical T1D diabetes induction (Alloxan), signs of development of early diabetic kidney disease such as distorted and enlarged glomeruli become apparent (B) compared to normal healthy (control) conditions (A). Quantitative analysis of the glomerulus area (in pixels) was performed in control mice and alloxan-induced diabetic mice. The diabetic group exhibited a significant increase in glomerulus area indicating glomerular hypertrophy, a characteristic feature of diabetic nephropathy(C). (D) BUN levels were significantly elevated in the diabetic group compared to healthy controls, indicating the development of diabetic kidney disease.
Islet Atrophy and Reduced Plasma C-Peptide Levels Following Alloxan-Induced T1D in Mice
Following chemical T1D diabetes induction (Alloxan), compared to control mice (A) type 1 diabetic mice show islet atrophy (B). Drop in mouse c-peptide plasma as a surrogate marker for insulin is observed in alloxan-type 1 induced mice compared to control mice.
Imaging of Transplanted Islets in Diabetic Mouse Model
(A) brightfield microscopy of transplanted islets under the kidney capsule in a diabetic mouse model. (B) immunofluorescent staining of the same islets, with pancreatic beta cells stained for insulin (green) and pancreatic alpha cells stained for glucagon (red). Nuclei are counterstained with DAPI (blue).
Glucose measurement for chemically induced and insulin treated diabetic mice after 14 days
Examine in vivo functionality of transplanted islet cell preparation after transplantation under the kidney capsule or subcutaneous transplantation sites. C-peptide levels are followed up to discriminate between insulin secreted by the mouse pancreas islets and transplanted cells. Diabetes reversal can be used to show therapeutic efficacy of your cell therapy product
Static Glucose Stimulated Insulin Secretion (GSIS) Assay
Static GSIS assays can be performed to examine the effects on insulin secretion after glucose stimulation. The assay can be performed with cell lines (INS1E, MIN6) or primary cell preparations.
Related model options
Immunology Models Overview
Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence.
mRNA/RNA Therapies
Vaccine Testing and mRNA/RNA therapies: LNP delivery, in vitro assays, biodistribution, PKPD, immunogenicity, dose optimization and more
IL-23 Induced Psoriasis Mouse Model
Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute IL-23-Induced Psoriasis Mouse model.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.